PPARγ Pro12Ala Polymorphism in HIV-1-Infected Patients with HAARTRelated Lipodystrophy
Maria Saumoy, Sergi Veloso, Carlos Alonso-Villaverde, Pere Domingo, Matilde R. Chacon, Merce Miranda, Montserrat Broch, Gerard Aragones, M Mar Gutierrez, Consuelo Vilades, Joaquim Peraire, Joan-Josep Sirvent, Miguel Lopez-Dupla, Carmen Aguilar, Teresa Auguet, Joan Vendrell, Montserrat Olona, Cristobal Richart and Francesc Vidal
Pages 533-540 (8)
Peroxisome proliferator-activated receptor gamma (PPARγ) is involved in obesity and in some components of the metabolic syndrome in unselected population. To determine whether PPARγ genetic variants are associated with the risk of developing lipodystrophy and its associated metabolic disturbances in HIV-1-infected patients treated with HAART and to assess PPARγ mRNA expression in subcutaneous adipose tissue (SAT). The study group comprised 278 patients infected with HIV-1 and treated with antiretroviral drugs (139 with lipodystrophy and 139 without) and 105 uninfected controls (UC). The PPARγ Pro12Ala (C > G) single nucleotide polymorphism (SNP) was assessed using PCRRFLPs on white cell DNA. PPARγ mRNA expression in SAT was assessed in 38 patients (25 with lipodystrophy and 13 without) and in 21 UC by real-time PCR. Statistical analysis was based on Students T tests, 2 tests, Spearmans correlations tests and logistic regression tests. PPARγ Pro12Ala genotype distribution and allele frequencies were nonsignificantly different between both HIV-1-infected categories, lipodystrophy vs non-lipodystrophy (p = 0.9 and p = 0.87, respectively). Lipodystrophic patients harbouring the rare X/Ala genotype (Ala/Ala plus Pro/Ala) had significantly greater plasma total and LDL cholesterol levels compared with carriers of the common Pro/Pro genotype (p = 0.029 and p = 0.016, respectively) at univariate analyses. At multivariate analyses these associations were no longer significant. There was a near-significant decreased SAT PPARγ mRNA expression in patients with lipodystrophy compared to UC (p = 0.054). PPARγ Pro12Ala SNP has no effect on the risk of developing lipodystrophy in HIV-1-infected patients treated with HAART. PPARγ mRNA SAT expression appears decreased in lipodystrophy.
HIV, Lipodystrophy, dyslipidaemia, PPARγ, Polymorphism, Pharmacogenetics
Infectious Diseases and HIV/AIDS Section, Department of Internal Medicine, Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Mallafre Guasch, 4. 43007 Tarragona, Spain.